For example, people at risk for transient ischemic attacks, previous surgery, heart attack or other non-preventable risk factors for stroke may benefit from elevated GLT-1 levels caused by focal pharmacological [13], [14], [15] or genetic manipulation as less invasive and selective delivery of genes to the brain emerges. The gene discussed is SLC1A2; the disease is stroke disorder.